老年2型糖尿病合并非酒精性脂肪肝患者应用阿托伐他汀治疗的降脂疗效及安全性观察

摘要

Objective: To observe effect of Atorvastatin on lowering blood lipid in patients with type 2 diabetic mellitus plus non-alcoholic fatty liver. Methods: 39 cases of old patients were selected and given Atorvastatin 20 mg every night for 6 months. The levels of total cholesterol(TC), triglycerides(TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), serum alanine (Cr) were examined before and 3, 6 months after the treatment. Results: TC [(5.03±0.74) mmol/L ^ (3.14±0.43)mmol/L], TG [(1.91 ±0.40) mmol/L vs (1.21±0.56) mmol/L],LDL-C [(3.01 ±0.78) mmol/L vs (1.64±0.31) mmol/L] were significantly decreased 6 months after the treatment (P<0.01). No significant changes were observed in ALT, AST and Cr. Conclusion: Atorvastatin may significantly decrease the level of blood lipid with little adverse effect in elderly patients with type 2 diabetic mellitus plus non-alcoholic fatty liver.%目的:观察阿托伐他汀对老年2型糖尿病合并非酒精性脂肪肝患者降脂疗效和安全性.方法:选择老年2型糖尿合并非酒精性脂肪肝患者39例,每晚睡前服用阿托伐他汀20 mg,疗程为6个月.治疗前及治疗后3、6个月分别测定血总胆固醇(TC),三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白(LDL-C)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、血糖、肌酐(Cr).结果:阿托伐他汀治疗6个月后,患者TC、TG、LDL-C均显著降低 [(5.03±0.74)mmol/L至(3.14±0.43)mmol/L,(1.91±0.40)mmol/L至(1.21±0.56)mmol/L,(3.01±0.78)mmol/L至(1.64±0.31)mmol/L],前后差异均有高度统计学意义(均P＜0.01).治疗期间,ALT、AST、Cr未出现明显变化.结论:阿托伐他汀对老年2型糖尿病合并非酒精性脂肪肝患者有明显降脂效果,不良反应小.